loading page

Upfront Neck Dissection in Chemoradiotherapy for p16-Negative Oropharyngeal Cancer with Neck Metastases: A Retrospective study
  • +7
  • Wei Chen Fang,
  • Tsung Lun Lee,
  • Shyh-Kuan Tai,
  • Chia-Fan Chang,
  • Yen-Bin Hsu,
  • Pen-Yuan Chu,
  • Yi-Fen Wang,
  • Muh-Hwa Yang,
  • Peter Mu-Hsin Chang,
  • Ling-Wei Wang
Wei Chen Fang
Taipei Veterans General Hospital
Author Profile
Tsung Lun Lee
National Yang-Ming University
Author Profile
Shyh-Kuan Tai
Taipei Veterans General Hospital
Author Profile
Chia-Fan Chang
Taipei Veterans General Hospital
Author Profile
Yen-Bin Hsu
Taipei Veterans General Hospital
Author Profile
Pen-Yuan Chu
Taipei Veterans General Hospital
Author Profile
Yi-Fen Wang
Taipei Veterans General Hospital
Author Profile
Muh-Hwa Yang
National Yang-Ming University
Author Profile
Peter Mu-Hsin Chang
Taipei Veterans General Hospital
Author Profile
Ling-Wei Wang
Taipei Veterans General Hospital
Author Profile

Abstract

Objective: To determine the role of upfront neck dissection (ND) in patient survival and regional control of p16-negative oropharyngeal squamous cell carcinoma (OPSCC) with neck metastases. Design: Retrospective study. Participants: Patients with p16-negative OPSCC with neck metastases, diagnosed between January 1, 2011 and December 31, 2017, and treated with upfront ND followed by chemoradiotherapy (ND + CCRT) or primary chemoradiotherapy (CCRT). Main outcome measures: Recurrence and survival rates were analysed using the Kaplan-Meier method. Results: Data of 67 patients with p16-negative cN+ OPSCC were analysed. Of them, 23 (34.3%) received ND + CCRT and 44 (65.7%) received primary CCRT. At a median follow-up of 37.9 months, the 3-year neck recurrence rate was significantly lower in the ND + CCRT group than in the CCRT group (0% vs. 19%, p=0.031). This trend was more obvious in patients with neck metastases ≥3 cm (0% vs. 32.1%, p=0.045). Survival outcomes were comparable between the groups; notably, the ND + CCRT group received a significantly lower dose of radiotherapy (3-year disease-specific survival: 77.3% and 75.3%, p=0.968, respectively; 3-year disease-free survival: 77.3% and 70.1%, p=0.457, respectively; 3-year overall survival: 62% and 61.8%, p=0.771, respectively between the ND + CCRT and CCRT groups). Conclusion: Upfront ND was significantly beneficial for regional control and resulted in comparable oncological outcomes with a significantly reduced radiation dose. These results findings can help guide the development of a standardised treatment plan for p16-negative OPSCC. Additional prospective studies with larger sample sizes are warranted.